

Mechanisms of sepsis-induced cardiac dysfunction

Alain Rudiger, MD; Mervyn Singer, MD, FRCP

Objectives: To review mechanisms underlying sepsis-induced cardiac dysfunction in general and intrinsic myocardial depression in particular.

Data Source: MEDLINE database.

Data Synthesis: Myocardial depression is a well-recognized manifestation of organ dysfunction in sepsis. Due to the lack of a generally accepted definition and the absence of large epidemiologic studies, its frequency is uncertain. Echocardiographic studies suggest that 40% to 50% of patients with prolonged septic shock develop myocardial depression, as defined by a reduced ejection fraction. Sepsis-related changes in circulating volume and vessel tone inevitably affect cardiac performance. Although the coronary circulation during sepsis is maintained or even increased, alterations in the microcirculation are likely. Mitochondrial dysfunction, another feature of sepsis-induced organ dysfunction, will also place the cardiomyocytes at risk of adenosine triphosphate depletion. However, clinical studies have demonstrated that myocardial cell death is rare and that cardiac function is fully reversible in survivors. Hence, functional rather than structural changes seem to be responsible for intrinsic myocar-

dial depression during sepsis. The underlying mechanisms include down-regulation of β -adrenergic receptors, depressed post-receptor signaling pathways, impaired calcium liberation from the sarcoplasmic reticulum, and impaired electromechanical coupling at the myofibrillar level. Most, if not all, of these changes are regulated by cytokines and nitric oxide.

Conclusions: Integrative studies are needed to distinguish the hierarchy of the various mechanisms underlying septic cardiac dysfunction. As many of these changes are related to severe inflammation and not to infection *per se*, a better understanding of septic myocardial dysfunction may be usefully extended to other systemic inflammatory conditions encountered in the critically ill. Myocardial depression may be arguably viewed as an adaptive event by reducing energy expenditure in a situation when energy generation is limited, thereby preventing activation of cell death pathways and allowing the potential for full functional recovery. (Crit Care Med 2007; 35:1599–1608)

KEY WORDS: sepsis; heart failure; β -adrenergic receptors; mitochondria; nitric oxide; calcium signaling

Sepsis, the systemic inflammatory response syndrome to infection, is the leading cause of death in the critically ill (1, 2), predominantly as a consequence of multiple organ failure. Myocardial dysfunction is a recognized manifestation of this syndrome (3–6). In light of a greater understanding of the underlying pathophysiology, a reappraisal of the literature is warranted. We will review both clinical and preclinical studies and integrate recent insights into subcellular mechanisms. Our aim is to provide a detailed

overview on sepsis-induced cardiac dysfunction in general and on intrinsic myocardial depression in particular. The wide variety of possible pathophysiologic mechanisms and space limitations do not permit total coverage, but we hope that a synthesis of current knowledge relating to the major areas has been encapsulated in this review (Fig. 1).

PATIENT STUDIES

Despite awareness of sepsis-induced myocardial dysfunction for several decades, its frequency remains unknown. Large epidemiologic studies are lacking, and no consensus exists for a suitable definition. A reduced ejection fraction (EF) was recorded in 25% of nonshocked (7) and 50% of shocked septic patients (8) as assessed by ventriculography and thermodilution. However, cardiac output was normal or increased in all patients despite moderate to severe myocardial depression. Notably, survivors had lower EF and higher end-diastolic volumes compared with nonsurvivors, suggesting a protective effect of myocardial depression. The decrease in EF was reversible,

with full recovery of cardiac function seen in survivors at 7–10 days. Right heart dilation and decreased right ventricular EF have also been described in some studies (9, 10) although not in other studies (11).

More recent studies have predominantly used echocardiography. In newly presenting hypotensive patients, hyperdynamic left ventricular (LV) function (EF >55%) during initial resuscitation was an independent predictor of sepsis (12). In a sequential study (13), hemodynamically unstable patients in septic shock had normal LV end-diastolic volume but depressed LVEF and severely reduced stroke volumes. One in six had severe hypokinesia with LVEF <30%. LV end-diastolic volume subsequently increased in survivors but tended to decrease in nonsurvivors. In other studies of septic shock lasting ≥ 48 hrs, 24% to 44% had systolic LV dysfunction (14–16). Those with myocardial depression had received more fluids during the first 24 hrs of intensive care unit stay and suffered a higher overall mortality than patients without myocardial dysfunction (16). A

From the Bloomsbury Institute of Intensive Care Medicine, Wolfson Institute for Biomedical Research and Department of Medicine, University College London, UK.

Supported, in part, by the Stiefel Zangger Foundation and the Siegenthaler Foundation (AR), both in Zurich, Switzerland.

The authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: m.singer@ucl.ac.uk

Copyright © 2007 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/01.CCM.0000266683.64081.02




Figure 1. Sepsis-induced cardiac dysfunction. Cardiac performance during sepsis is impaired due to changes in the macro- and microcirculation, autonomic dysfunction, and inflammation-induced intrinsic myocardial depression. The mechanisms of myocardial depression include down-regulation of adrenergic pathways, disturbed intracellular calcium (Ca^{2+}) trafficking, and impaired electromechanical coupling at the myofibrillar level. Mitochondrial dysfunction seems to play a central role in this sepsis-induced organ dysfunction.

further 44% showed echocardiographic features of diastolic dysfunction (15).

Various biomarkers have identified septic patients with cardiac injury or dysfunction. Serum levels of troponin I or T, both sensitive markers of cardiomyocyte damage, are elevated in 31% to 85% of critically ill patients with sepsis (17–21). Elevated troponin levels were associated with higher catecholamine requirements (18), lower stroke work index (18) and LVEF (20), and a higher mortality (17–20). Apart from necrosis, cytoplasmic troponin can leak into the circulation after reversible damage to the cardiac contractile apparatus (22). As discussed later, widespread myocardial necrosis is not a feature of human sepsis.

Elevated B-type natriuretic peptide levels have also been used to identify cardiac dysfunction in septic patients (16, 23), although many factors influence B-type natriuretic peptide levels, including age, gender, renal function (24), and possibly inflammation (25). We reported a similar increase in B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure (26). High B-type natriuretic peptide levels in sepsis also correlated with adverse outcomes (16, 27).

ANIMAL MODELS

In vivo and *ex vivo* assessments have been performed using LV pressure measurements (28–30), conductance cath-

eters (31, 32), echocardiography (28, 30, 33, 34), positron emission tomography (34), magnetic resonance spectroscopy (35), radionuclide studies (35, 36), and the Langendorff perfused heart model (37, 38). Investigators have also performed light and electron microscopy of cardiac tissue (35) and assessed isolated papillary muscles (39, 40), permeabilized muscle fibers (41), and single cardiomyocytes (42, 43). These models have varied in type (e.g., endotoxin, infusion of live bacteria, cecal ligation and puncture) and severity of insult, species, duration of study, anesthesia, and the degree (or absence) of volume resuscitation. The physiologic and immunologic response will vary as a consequence (44) and will affect outcome (45).

MECHANISMS

Circulatory and Microvascular Changes

Early sepsis and septic shock are characterized by circulatory abnormalities that usually relate to intravascular volume depletion and vasodilation. Consequently underfilling of the heart leads to a reduced cardiac output. This potentially causes an oxygen supply-demand imbalance in various organ beds (46) that is often reversed by fluid resuscitation (47). Insufficiently resuscitated animal models are therefore likely to demonstrate reduced cardiac performance (34, 48, 49).

Myocardial edema due to inflammation-induced vascular leakage may also influence cardiac compliance and function (34, 50). In addition, ventricular function is influenced by changes in afterload. Pulmonary hypertension will worsen right heart function (51), whereas right heart dilation will impair left heart function (52). Finally, intrinsic cardiac contractility is affected, with a decreased ventricular performance in response to fluid resuscitation (53).

Macrocirculatory coronary blood flow is increased in patients with established septic shock (54, 55), but debate is ongoing as to the role of the microcirculation. In endotoxemic dog hearts, heterogeneous cardiac microvascular blood flow (56), swelling of endothelial cells, and nonocclusive intravascular fibrin depositions (35) are reported. Nevertheless, Hotchkiss et al. (57) found no cellular hypoxia in septic rat hearts using the marker ^{18}F fluoromisonidazole.

Vascular endothelial cells and cardiac myocytes interact closely. Endothelial cell activation led to increased production of nitric oxide (NO), endothelin, and prostaglandins that had paracrine regulatory effects on cardiac function (58). NO from activated endothelial cells also impaired isometric contractions of isolated cardiac trabeculae (59, 60). On the other hand, activated cardiomyocytes from septic mice influenced endothelial barrier function and promoted transendothelial migration of circulating neutrophils into the cardiac interstitium (61).

Autonomic Dysregulation

Some authors argue that severe sepsis is characterized by an autonomic failure, perhaps related to apoptosis in cardiovascular autonomic centers (62), that can precede the onset of shock (63–65). Tachycardia, a typical sepsis feature, is viewed as a response to cardiac underfilling, adrenergic stimulation, and fever. Sepsis-related tachycardia has several adverse effects on the heart, including restricted diastolic ventricular filling, increased oxygen requirements, and, potentially, a tachycardia-induced cardiomyopathy. Indeed, heart rate on presentation predicted survival in septic shock patients (66).

Metabolic Changes

Metabolic changes in the normal and diseased heart have been reviewed exten-

sively (67). During sepsis, profound metabolic changes are suggested by intracardiac accumulation of lipids and glycogen in nonsurvivors (22) and in mice (68). Whereas sepsis is characterized by hyperlactatemia, the hearts of septic patients show a net lactate extraction between arterial and coronary sinus blood (54) and a diminished myocardial uptake of glucose, ketone bodies, and free fatty acids (55). In septic patients, oxygen consumption and resting metabolic rate are enhanced compared with normal metabolism (69). However, with the development of organ dysfunction and the progression of shock, both oxygen consumption and resting metabolic rate decrease. This suggests that septic patients with established organ dysfunction or shock can tolerate lower values of oxygen delivery. Prolonged sepsis is also associated with a progressive increase in tissue oxygen tension that parallels the severity

of illness (70, 71). The implication is that the problem lies more in reduced cellular oxygen utilization than in its delivery to tissues. As >90% of total body oxygen consumption is used by mitochondria for adenosine triphosphate (ATP) production, mitochondria may play a fundamental role in the pathogenesis of sepsis-induced organ dysfunction.

Mitochondrial Dysfunction

Many sepsis studies demonstrate the importance of mitochondrial dysfunction (72, 73) (Fig. 2). This has been linked to both severity and outcome (74). Cardiomyocytes demonstrate mitochondrial ultrastructural damage in both septic animals (35, 75–78) and patients (79, 80). Reduced oxygen consumption, suggestive of disturbed mitochondrial respiratory function, is described in animals in late but not early-stage sepsis (77). Decreased

activities of mitochondrial electron transport chain enzyme complexes are also documented in hearts from septic animals (43, 76, 81–83). Underlying mechanisms include the inhibitory effects of reactive nitrogen and oxygen species on oxidative phosphorylation and ATP production. This is related to elevated production of superoxide and NO and depletion of intramitochondrial antioxidants (74). Mitochondrial DNA is more susceptible to endotoxin-induced damage than nuclear DNA (76, 84). However, reactive oxygen species will also stimulate recovery by activating mitochondrial biogenesis within the rat heart (76).

Increased expression of mitochondrial uncoupling proteins (UCP) could reduce mitochondrial membrane potential and ATP synthesis (85, 86). UCP1 in brown adipose tissue is linked with heat production, whereas the roles of UCP2 and UCP3, both found in human heart (87), are less clear, especially during sepsis (88). A UCP-induced proton leak may reduce the efficiency of ATP generation but could also potentially limit superoxide generation (89). Heat shock proteins, strategically positioned in and outside mitochondria, protect vital protein structures and functions during stress conditions (90). Their activation in septic rats reduced cardiac mitochondrial dysfunction (91) and mortality (92). Finally, the mitochondrial permeability transition pore may also play a role in the development of mitochondrial dysfunction, as its inhibition improved mitochondrial respiration, restored the cardiomyocyte membrane potential, improved cardiac function *ex vivo*, and reduced mortality in septic mice (93).




Figure 2. Mitochondrion. *A*, electrons passing along the respiratory chain complexes generate a proton (H^+) gradient across the inner mitochondrial membrane that drives adenosine triphosphate (ATP) synthesis. At complex IV, most of the oxygen consumed by mitochondria is reduced to water. Other oxygen molecules react with free electrons at complexes I and III, resulting in production of superoxide ($O_2^{\bullet -}$) and, subsequently, other reactive oxygen species (ROS). Uncoupling proteins (UCP) dissipate the proton gradient, thereby potentially reducing ATP and ROS production. Opening of the permeability transition pore (PTP) results in mitochondrial swelling, proton gradient collapse, calcium efflux, and release of cytochrome *c* (CytC), an activator of apoptosis. Sepsis induces mitochondrial dysfunction at various levels, partly by excessive nitric oxide (NO) production. *B*, ATP binds to actin, allowing myosin to detach from its binding site and change its configuration, a process that is crucial for myocardial relaxation. ADP, adenosine diphosphate.

Cell Death

Cellular hypoxia (due to circulatory derangements) and dysoxia (due to mitochondrial dysfunction) may both place the cardiomyocyte at risk of energy depletion and cell death if energy demands continue to outstrip supply. In different septic models, variable changes in ATP and phosphocreatine have been reported (35, 75, 94). In some of these studies, myocardial depression was noted in the absence of any changes in high-energy phosphates or cell death. However, nucleotide levels may be preserved by a reduction in energy requirements (74), and a decrease in ATP turnover cannot be excluded.

With regard to myocardial cell death, postmortem studies in septic shock patients revealed increased inflammatory cell infiltration but minimal, if any, myocardial cell death (20, 22, 80, 95, 96). Animal studies have detected subendocardial necrosis after non-fluid-resuscitated sepsis (97), although other studies have shown negligible myocardial necrosis (35) or apoptosis (98–102). Of note, the caspase cascade is nonetheless activated. A caspase inhibitor reduced the degree of depression in *ex vivo* Langendorff heart preparations and in isolated cardiomyocytes (101), hinting at alternative modes of action. In summary, myocardial cell death is a rare event during sepsis and insufficient to account for the functional depression observed. The reversibility of this condition also supports functional rather than anatomical abnormalities.

Inflammatory Signaling

Endotoxin, Toll-Like Receptors, and Cytokines. Endotoxin mediates cardiovascular changes mimicking sepsis in both research animals (103) and human volunteers (104–106). Endotoxin-induced cardiac dysfunction depends on the presence of the cell-wall receptors Toll-like receptor-4 (30, 43, 107) and CD14 (108). Toll-like receptor-4 must be present on macrophages and, to a lesser extent, neutrophils to cause myocyte dysfunction during endotoxemia (43, 109). Likewise, Toll-like receptor-2 is necessary for myocardial dysfunction after a Gram-positive challenge (110). These studies thus invoke a mechanism involving cytokine release from macrophages, supporting earlier work from Parrillo et al. (42) identifying the presence of a circulating myocardial depressant substance in humans with septic shock. Serum from these patients taken during the acute phase, but not the recovery period, significantly depressed contractions in isolated rat cardiomyocytes. These *in vitro* changes paralleled serial changes seen in the patients' LVEF. Immunoabsorption of both tumor necrosis factor α and interleukin-1 β from the patient sera resulted in loss of depressant activity in the rodent cells (111). This study also showed a dose- and time-dependent decrease of myocardial cell shortening after cytokine treatment, which reversed on washing the cells with cytokine-free media. Interleukin-6 has also been shown to have an important role in myocardial depressant

activity in children with meningococcal septic shock (112). This supported earlier work in *in vitro* models (113, 114). Macrophage migration inhibitory factor, another proinflammatory cytokine elevated in patients with septic shock, is also implicated in the pathogenesis of myocardial dysfunction (115–117). In summary, myocardial function is depressed by various cytokines produced and liberated from activated immune cells after contact with bacterial compounds.

Nitric Oxide. NO, a small, highly reactive molecule with a half-life of a few seconds, is produced in virtually all cell types within the heart. All three isoforms of NO synthase (NOS) are found in cardiomyocytes. NO has a multifaceted role in cardiac physiology, both in health and disease states, and its biology is highly complex (see Refs. 118–120 for reviews). It is responsible for direct effects on vascular tone, depression of mitochondrial respiration, and further release of proinflammatory cytokines. NO is also endowed with pro- or antiapoptotic signaling capabilities, depending to some extent on its concentration and cellular context, for example, generation of reactive oxygen species (121, 122).

The inducible NOS-2, transcriptionally up-regulated by cytokines, pathogen antigens, and redox-sensitive transcription factors, produces NO, a well-recognized myocardial depressant (123–125). Conflicting results from selective and nonselective inhibition of inducible NO synthase indicate that the constitutive NOS isoforms (NOS-1 and NOS-3) have a potential role in regulating cardiomyocyte homeostasis and function (39, 126, 127). Whereas NOS-2 activation depressed cardiac function, overexpression of NOS-3 had the opposite effect in septic mice (128). These differences may be related to variable dose-related, temporal, and subcellular compartmental effects on β -adrenergic responsiveness, calcium handling, and contractility (129).

NO activates soluble guanylyl cyclase, thus elevating intracellular 3'5'-cyclic guanosine monophosphate and, in turn, a family of 3'5'-cyclic guanosine monophosphate kinases. NO also reacts with superoxide to form peroxynitrite (ONOO⁻). NO and ONOO⁻ can react with iron and thiol-containing proteins to modulate the role of that protein either reversibly or irreversibly, for example, enzyme activity. ONOO⁻ induced a delayed and irreversible cardiac depression in a perfused heart model (130). Myocardial ATP levels

remained normal, as did creatine kinase release, indicating a lack of myocyte death. The same group also reported similar findings, with increased ventricular NOS-2 activity and levels of NO and ONOO⁻, in hearts perfused with either cytokines (123) or endotoxin (131). A peroxynitrite decomposition catalyst, a NO synthase inhibitor, and a superoxide scavenger were all able to prevent this decline in cardiac function. Some of these results may be explained by ONOO⁻-induced activation of matrix metalloproteinases (132).

Conservation of the NOS-2 gene during evolution suggests that the NO response to sepsis could be adaptive and, at least in part, protective to the heart. Indeed, selective NOS-2 inhibition increased cardiac oxygen consumption in failing dog hearts (133). NO also induces coronary and systemic vasodilation, thereby facilitating myocardial blood supply and reducing cardiac afterload. NOS-2 inhibition increased systemic and pulmonary blood pressure but decreased cardiac output in endotoxin-treated animals (51, 134, 135) and in septic shock patients (136, 137). Furthermore, NO may increase ventricular compliance, allowing the septic heart to fill more easily during diastole (138, 139). By inhibiting the electron transport chain, NO and ONOO⁻ could decrease superoxide production (89). NO can additionally act as a free radical scavenger, preventing the formation of even more toxic reactive oxygen species (140). Finally, if organ failure is related to mitochondrial damage, recovery will be contingent on restoration of new active mitochondrial protein. This process, mitochondrial biogenesis, is triggered by NO (141, 142).

Contractile Dysfunction

Adrenergic Signaling. Short-term β -adrenergic stimulation with catecholamines increases cardiac contractility and heart rate. However, prolonged and excess stimulation can lead to myocardial damage by calcium overload and consequent cell necrosis (143). During sepsis, various studies have documented elevated catecholamine levels in patients (63, 144, 145) and animals (33, 146). Circulating catecholamines may be auto-oxidized by superoxide and thus inactivated (147). In a septic shock rat model, administration of a superoxide dismutase mimetic increased plasma catecholamine concentrations and β -adrenergic respon-




Figure 3. Adrenergic signaling. After stimulation of cardiac autonomic centers, secreted catecholamines stimulate β -adrenergic receptors (βAR) on cardiomyocytes. These receptors are coupled to adenylate cyclase (AC), which transforms adenosine triphosphate (ATP) to cyclic adenosine monophosphate ($cAMP$). G-proteins, both stimulatory (G_s) and inhibitory (G_i), modify signal transmission across the cell membrane. $cAMP$ activates protein kinase A (PKA), which phosphorylates key enzymes that stimulate metabolism, stimulate cardiomyocyte contraction and relaxation, and influence heart rate. Sepsis induces a disruption at various levels of this signaling cascade, partly via nitric oxide (NO), cyclic guanosine monophosphate ($cGMP$), and protein kinase G (PKG).

siveness. At the cardiomyocyte level, various adaptive mechanisms responding to elevated catecholamine levels have been identified (Fig. 3). In septic rats, myocardial β -adrenergic receptor density was found to be decreased (148, 149). Others found a blunted contractile response in rat cardiomyocytes after cytokine stimulation despite a normal receptor density (150). Notably, responses to increased extracellular calcium ion concentrations were normal. The underlying mechanism was identified to be a disruption of signal transduction across the cell membrane (151). In endotoxemic rabbits, stimulatory G-proteins were decreased (152), whereas in both nonsurvivors of septic shock (153) and septic animals (154), inhibitory G-proteins were increased. These changes result in decreased activity of adenylate cyclase and reduced levels of cyclic adenosine monophosphate. In summary, β -adrenergic stimulation during sepsis is blunted by alterations occurring

at different levels of the signaling cascade. In both patients with reduced LV function (155) and septic mice (156), down-regulation of the β -adrenergic response was associated with elevated levels of NO.

Calcium Trafficking. Intracellular calcium trafficking is depicted in Figure 4. Endotoxin (157, 158) and cytokines (159) alter and suppress L-type calcium currents in isolated rat cardiomyocytes, perhaps via changes in autonomic regulation of this channel. This is accompanied by reduced systolic intracellular calcium concentration and diminished cell contraction. Additionally, endotoxin opens ATP-dependent potassium channels, thereby shortening action potentials and reducing calcium overload (160). Ryanodine receptor density is also decreased in septic models, with a consequent impairment of calcium-induced calcium release (161, 162). Ryanodine receptor activity and isolated papillary muscle contractility were decreased at 24 hrs but not 4 hrs

after endotoxin (163). These effects could be reversed by selective NOS-2 inhibition. Recombinant human tumor necrosis factor- α decreased contractility in *in vitro* models (164), secondary to a decrease in intracellular calcium concentration, perhaps via activation of the sphingomyelin pathway (165–167). Tumor necrosis factor- α -dependent degradation of sphingomyelin to sphingosine blocks the ryanodine receptor and impedes calcium release from the sarcoplasmic reticulum.

Diastolic calcium uptake into the sarcoplasmic reticulum was unaffected during the early phase of sepsis but decreased later on (168, 169). This was associated with defective phosphorylation of sarcoplasmic reticulum proteins, including phospholamban, and an increase in tissue cyclic adenosine monophosphate, implicating changes in β -adrenergic signaling.

The phosphatase calcineurin stimulates cytokine gene transcription and opens the mitochondrial permeability transition pore. Inhibition of calcineurin normalized cardiac performance 4 hrs after endotoxin, preventing cardiomyocyte apoptosis (170) and improving mitochondrial morphology and function (171). However, these changes were accompanied by a probable increase in reactive oxygen species (171).

In summary, reductions in cytosolic calcium levels reduce contractility during late sepsis. Calcium trafficking is also linked to mitochondrial function and integrity. It remains to be determined how these effects on calcium signaling are linked to time-dependent changes in NO, the β -adrenergic response, and any protective effects on the myocardium during prolonged sepsis.

Myofibrillar Dysfunction. In nonsurvivors of long-standing septic shock, immunohistochemical analysis of cardiomyocytes suggested partial disruption of myofilaments (22). This may be due to enhanced matrix metalloproteinase activity as these enzymes can degrade both the contractile apparatus and the cytoskeleton (172, 173). Reversal of these structural changes is likely to be slow, especially if *de novo* protein synthesis is required. An altered calcium sensitivity of cardiac myofibrillar proteins is seen in animal models of sepsis (174, 175), leading to reduced contractility of isolated papillary muscles (40). In summary, alterations of the contractile apparatus, including reduced calcium sensitivity, are also likely to contribute to the myocardial depression during sepsis.




Figure 4. Calcium trafficking. *A*, depolarization of the cardiomyocyte sarcolemma opens L-type voltage gated calcium channels (*L*), leading to Ca^{2+} -induced Ca^{2+} release by ryanodine receptors (*RyR*) from the sarcoplasmic reticulum (*SR*). The intracellular Ca^{2+} concentration determines the force of contraction. To allow diastolic relaxation, Ca^{2+} must be removed from the cytosol back into the SR by the energy-dependent SR-calcium-adenosine triphosphatase (SERCA). SERCA activity is regulated by phospholamban (*Ph*). A proportion of Ca^{2+} is removed into mitochondria, and some is transported extracellularly by a Na^{+} - Ca^{2+} pump. Some Ca^{2+} binds to calmodulin (*CM*), a regulatory protein that lowers cytosolic Ca^{2+} directly, and via calmodulin-kinase (*CMK*), which stimulates Ca^{2+} reuptake into the SR. CMK also activates calcineurin (*CN*), which interacts with the mitochondrial permeability transition pore, enabling mitochondria-related death pathways. Sepsis inhibits intracellular Ca^{2+} trafficking at various sites. *B*, cytosolic Ca^{2+} binds to troponin C (*Tc*), modulating the inhibitory action of troponin I (*Ti*) and tropomyosin, hence exposing the binding site for myosin. After interaction between actin and myosin, the myosin head changes its conformation, resulting in a power stroke that moves the actin filament against the myosin filament. Sepsis decreases calcium sensitivity and causes damage to the contractile apparatus via activation of matrix metalloproteinases.

CONCLUSIONS

Myocardial depression is a well-recognized manifestation of organ dysfunction in sepsis. Echocardiographic studies suggest that 40% to 50% of patients with prolonged septic shock develop myocardial depression, as defined by a reduced ejection fraction. The degree of myocardial structural derangement and functional impairment relates to the severity of illness. As sicker patients usually receive higher doses of vasoactive drugs, the physiologic cardiac response may be masked considerably. Various mechanisms can explain the development of septic myocardial depression, most of which are regulated by cytokines and NO. Future integrative studies are needed to distinguish the importance and hierarchy of these mechanisms. As many of the changes described here are related to severe inflammation and not to infection *per se*, a better understanding of septic myocardial dysfunction may be usefully extended to other systemic inflammatory conditions encountered in the critically ill.

Finally, it is worth considering that myocardial depression could protect the heart by reducing cellular energy expenditure in a situation when energy generation is impaired due to mitochondrial dysfunction and microcirculatory abnormalities. Analogies can be drawn to ischemia-induced hibernation, a well-recognized phenomenon in patients with ischemic heart disease, serving as a regulatory event that maintains myocardial integrity and viability (176). Similar cellular changes to those seen during hibernation have been reported in septic animals in conjunction with diminished cardiac performance (68). This concept merits further investigation as it may carry major implications for patient management.

REFERENCES

- Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; 348:138–150
- Annane D, Bellissant E, Cavaillon J-M: Septic shock. *Lancet* 2005; 365:63–78

- Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock. *Crit Care Clin* 2000; 16:251–287
- Court O, Kumar A, Parrillo JE, et al: Myocardial depression in sepsis and septic shock. *Crit Care* 2002; 6:500–507
- Levy RJ, Deutschman CS: Evaluating myocardial depression in sepsis. *Shock* 2004; 22:1–10
- Rabuel C, Mebazaa A: Septic shock: A heart story since the 1960s. *Intensive Care Med* 2006; 32:799–807
- Calvin JE, Driedger AA, Sibbald WJ: An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. *Chest* 1981; 80:579–586
- Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock. *Ann Intern Med* 1984; 100:483–490
- Parker MM, McCarthy KE, Ognibene FP, et al: Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. *Chest* 1990; 97:126–131
- Raper R, Sibbald WJ, Driedger AA, et al: Relative myocardial depression in normotensive sepsis. *J Crit Care* 1989; 4:9–18
- Vincent JL, Gris P, Coffernils M, et al: Myocardial depression characterizes the fatal course of septic shock. *Surgery* 1992; 111: 660–667
- Jones AE, Craddock PA, Tayal VS, et al: Diagnostic accuracy of left ventricular function for identifying sepsis among emergency department patients with nontraumatic symptomatic undifferentiated hypotension. *Shock* 2005; 24:513–517
- Jardin F, Fourme T, Page B, et al: Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. *Chest* 1999; 116:1354–1359
- Morelli A, De Castro S, Teboul J-L, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. *Intensive Care Med* 2005; 31:638–644
- Poelaert J, Declerck C, Vogelaers D, et al: Left ventricular systolic and diastolic function in septic shock. *Intensive Care Med* 1997; 23:553–560
- Charpentier J, Luyt C-E, Fulla Y, et al: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. *Crit Care Med* 2004; 32:660–665
- Spies C, Haude V, Fitzner R, et al: Serum cardiac troponin T as a prognostic marker in early sepsis. *Chest* 1998; 113:1055–1063
- Turner A, Tsamitros M, Bellomo R: Myocardial cell injury in septic shock. *Crit Care Med* 1999; 27:1775–1780
- Arlati S, Brenna S, Prencipe L, et al: Myocardial necrosis in ICU patients with acute non-cardiac disease: A prospective study. *Intensive Care Med* 2000; 26:31–37
- Ver Elst KM, Spapen HD, Nam Nguyen D, et al: Cardiac troponins I and T are biological

- markers of left ventricular dysfunction in septic shock. *Clinical Chemistry* 2000; 46: 650–657
21. Ammann P, Fehr T, Minder EI, et al: Elevation of troponin I in sepsis and septic shock. *Intensive Care Med* 2001; 27: 965–969
 22. Rossi MA, Celes MR, Prado CM, et al: Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. *Shock* 2007; 27:10–18
 23. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. *Intensive Care Med* 2003; 29:1696–1702
 24. McLean AS, Huang SJ, Nalos M, et al: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. *Crit Care Med* 2003; 31:2611–2618
 25. Ma KK, Ogawa T, de Bold AJ: Selective up-regulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. *J Mol Cell Cardiol* 2004; 36:505–513
 26. Rudiger A, Gasser S, Fischler M, et al: Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. *Crit Care Med* 2006; 34:2140–2144
 27. Tung RH, Garcia C, Morss AM, et al: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. *Crit Care Med* 2004; 32:1643–1647
 28. Kovacs A, Courtois MR, Barzilay B, et al: Reversal of hypocalcaemia and decreased afterload in sepsis. *Am J Respir Crit Care Med* 1998; 158:1990–1998
 29. Zhou M, Wang P, Chaudry IH: Cardiac contractility and structure are not significantly compromised even during the late, hypodynamic stage of sepsis. *Shock* 1998; 9: 352–358
 30. Nemoto S, Vallejo JG, Knuefermann P, et al: Escherichia coli LPS-induced LV dysfunction: Role of Toll-like receptor-4 in the adult heart. *Am J Physiol Heart Circ Physiol* 2002; 282:2316–2323
 31. Tao W, Deyo DJ, Traber DL, et al: Hemodynamic and cardiac contractile function during sepsis caused by cecal ligation and puncture in mice. *Shock* 2004; 21:31–37
 32. Aghajani E, Korvald C, Nordhaug D, et al: E. coli sepsis induces profound mechanoenergetic inefficiency in the porcine left ventricle. *Shock* 2004; 21:103–109
 33. Iwase M, Yokota M, Kitaichi K, et al: Cardiac functional and structural alterations induced by endotoxin in rats: Importance of platelet-activating factor. *Crit Care Med* 2001; 29:609–617
 34. Chagnon F, Bentourkia Mh, Lecomte R, et al: Endotoxin-induced heart dysfunction in rats: Assessment of myocardial perfusion and permeability and the role of fluid resuscitation. *Crit Care Med* 2006; 34:127–133
 35. Solomon MA, Correa R, Alexander HR, et al: Myocardial energy metabolism and morphology in a canine model of sepsis. *Am J Physiol Heart Circ Physiol* 1994; 266:757–768
 36. Natanson C, Fink MP, Ballantyne HK, et al: Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. *J Clin Invest* 1986; 78:259–270
 37. Hearse DJ, Sutherland FJ: Experimental models for the study of cardiovascular function and disease. *Pharmacol Res* 2000; 41: 597–603
 38. Sutherland FJ, Hearse DJ: The isolated blood and perfusion fluid perfused heart. *Pharmacol Res* 2000; 41:613–627
 39. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. *Science* 1992; 257:387–389
 40. Tavernier B, Mebazaa A, Mateo P, et al: Phosphorylation-dependent alteration in myofilament Ca²⁺ sensitivity but normal mitochondrial function in septic heart. *Am J Respir Crit Care Med* 2001; 163: 362–367
 41. Veksler VI, Kuznetsov AV, Sharov VG, et al: Mitochondrial respiratory parameters in cardiac tissue: A novel method of assessment by using saponin-skinned fibers. *Biochem Biophys Acta* 1987; 892:191–196
 42. Parrillo JE, Burch C, Shelhamer JH, et al: A circulating myocardial depressant substance in humans with septic shock. *J Clin Invest* 1985; 76:1539–1553
 43. Tavener SA, Long EM, Robbins SM, et al: Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. *Circ Res* 2004; 95:700–707
 44. Schlag G, Redl H, van Vuuren CJ, et al: Hyperdynamic sepsis in baboons: II. Relation of organ damage to severity of sepsis evaluated by a newly developed morphological scoring system. *Circ Shock* 1992; 38: 253–263
 45. Kinasewitz GT, Chang AC, Peer GT, et al: Peritonitis in the baboon: A primate model which stimulates human sepsis. *Shock* 2000; 13:100–109
 46. Hotchkiss RS, Karl IE: Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. *JAMA* 1992; 267:1503–1510
 47. Rivers E, Nguyen B, Havstad S, et al: Early-goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; 345:1368–1377
 48. Coalson JJ, Hinshaw LB, Guenter CA, et al: Pathophysiologic responses of the subhuman primate in experimental septic shock. *Lab Invest* 1975; 32:561–569
 49. Schlag G, Redl H, Hallstrom S, et al: Hyperdynamic sepsis in baboons: I. Aspects of hemodynamics. *Circ Shock* 1991; 34:311–318
 50. Yu P, Boughner DR, Sibbald WJ, et al: Myocardial collagen changes and edema in rats with hyperdynamic sepsis. *Crit Care Med* 1997; 25:657–662
 51. Cohen RI, Shapir Y, Chen L, et al: Right ventricular overload causes the decrease in cardiac output after nitric oxide synthesis inhibition in endotoxemia. *Crit Care Med* 1998; 26:738–747
 52. Moore TD, Frenneaux MP, Sas R, et al: Ventricular interaction and external constraint account for decreased stroke work during volume loading in CHF. *Am J Physiol Heart Circ Physiol* 2001; 281:2385–2391
 53. Ognibene FP, Parker MM, Natanson C, et al: Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. *Chest* 1988; 93: 903–910
 54. Cunnion RE, Schaer GL, Parker MM, et al: The coronary circulation in human septic shock. *Circulation* 1986; 73:637–644
 55. Dhainaut J-F, Huyghebaert M-F, François MJ, et al: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. *Circulation* 1987; 75:533–541
 56. Groeneveld AB, van Lambalgen AA, van den Bos GC, et al: Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. *Cardiovasc Res* 1991; 25: 80–88
 57. Hotchkiss RS, Rust RS, Dence CS, et al: Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F] fluoromisonidazole. *Am J Physiol Regul Integr Comp Physiol* 1991; 261:R965–R972
 58. Mebazaa A, De Keulenaer GW, Paqueron X, et al: Activation of cardiac endothelium as a compensatory component in endotoxin-induced cardiomyopathy: Role of endothelin, prostaglandins, and nitric oxide. *Circulation* 2001; 104:3137–3144
 59. Jacobs H, Mink SN, Duke K, et al: Characterization of membrane N-glycan binding sites of lysozyme for cardiac depression in sepsis. *Intensive Care Med* 2005; 31:129–137
 60. Mink SN, Bose R, Roberts DE, et al: Lysozyme binding to endocardial endothelium mediates myocardial depression by the nitric oxide guanosine 3',5' monophosphate pathway in sepsis. *J Mol Cell Cardiol* 2005; 39:615–625
 61. Madorin WS, Rui T, Sugimoto N, et al: Cardiac myocytes activated by septic plasma promote neutrophil transendothelial migration: Role of platelet-activating factor and the chemokines LIX and KC. *Circ Res* 2004; 94:944–951
 62. Sharshar T, Gray F, Lorin de la Grandmaison G, et al: Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. *Lancet* 2003; 362: 1799–1805

63. Annane D, Trabold F, Sharshar T, et al: Inappropriate sympathetic activation at onset of septic shock: A spectral analysis approach. *Am J Respir Crit Care Med* 1999; 160:458–465
64. Schmidt HB, Werdan K, Müller-Werdan U: Autonomic dysfunction in the ICU patient. *Curr Opin Crit Care* 2001; 7:314–322
65. Chan JY, Ou CC, Wang LL, et al: Heat shock protein 70 confers cardiovascular protection during endotoxemia via inhibition of nuclear factor-kappaB activation and inducible nitric oxide synthase expression in the rostral ventrolateral medulla. *Circulation* 2004; 110:3560–3566
66. Azimi G, Vincent J-L: Ultimate survival from septic shock. *Resuscitation* 1986; 14: 245–253
67. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. *Physiol Rev* 2005; 85:1093–1129
68. Levy RJ, Piel DA, Acton PD, et al: Evidence of myocardial hibernation in the septic heart. *Crit Care Med* 2005; 33:2752–2756
69. Kreyman G, Grosser S, Buggisch P, et al: Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. *Crit Care Med* 1993; 21:1012–1019
70. Boekstegers P, Weidenhöfer S, Pilz G, et al: Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: Comparison to limited infection and cardiogenic shock. *Infection* 1991; 19:317–323
71. Boekstegers P, Weidenhöfer S, Kapsner T, et al: Skeletal muscle partial pressure of oxygen in patients with sepsis. *Crit Care Med* 1994; 22:640–650
72. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. *Mitochondrion* 2004; 4: 729–741
73. Gellerich FN, Trumbeckaite S, Opalka JR, et al: Mitochondrial dysfunction in sepsis: Evidence from bacteraemic baboons and endotoxaemic rabbits. *Biosci Rep* 2002; 22: 99–113
74. Brealey D, Brand M, Hargreaves I, et al: Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet* 2002; 360:219–223
75. Watts JA, Kline JA, Thornton LR, et al: Metabolic dysfunction and depletion of mitochondria in hearts of septic rats. *J Mol Cell Cardiol* 2004; 36:141–150
76. Suliman HB, Welty-Wolf KE, Carraway MS, et al: Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. *Cardiovasc Res* 2004; 64:279–288
77. Schumer W, Erve PR, Obernolte RP: Endotoxemic effect on cardiac and skeletal muscle mitochondria. *Surg Gynecol Obstet* 1971; 133:433–436
78. Hersch M, Gnidec AA, Bersten AD, et al: Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. *Surgery* 1990; 107:397–410
79. Cowley RA, Merger WJ, Fisher RS, et al: The subcellular pathology of shock in trauma patients: Studies using immediate autopsy. *Am Surg* 1979; 45:255–269
80. Soriano FG, Nogueira AC, Caldini EG, et al: Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. *Crit Care Med* 2006; 34:1073–1079
81. Levy RJ, Vijayasathary C, Raj NR, et al: Competitive and noncompetitive inhibition of myocardial cytochrome C oxidase in sepsis. *Shock* 2004; 21:110–114
82. Trumbeckaite S, Opalka JR, Neuhof C, et al: Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. *Eur J Biochem* 2001; 268:1422–1429
83. Gellerich FN, Trumbeckaite S, Hertel K, et al: Impaired energy metabolism in hearts of septic baboons: Diminished activities of complex I and complex II of the mitochondrial respiratory chain. *Shock* 1999; 11: 336–341
84. Suliman HB, Carraway MS, Piantadosi CA: Postlipopolysaccharide oxidative damage of mitochondrial DNA. *Am J Respir Crit Care Med* 2003; 167:570–579
85. Krauss S, Zhang C-Y, Lowell BB: The mitochondrial uncoupling-protein homologues. *Nat Rev* 2005; 6:248–261
86. Brand MD, Esteves TC: Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. *Cell Metab* 2005; 2:85–93
87. Murray AJ, Anderson RE, Watson GC, et al: Uncoupling proteins in human heart. *Lancet* 2004; 364:1786–1788
88. Roshon MJ, Kline JA, Thornton LR, et al: Cardiac UCP2 expression and myocardial oxidative metabolism during acute septic shock in the rat. *Shock* 2003; 19:570–576
89. Ehtay KS, Roussel D, St-Pierre J, et al: Superoxide activates mitochondrial uncoupling proteins. *Nature* 2002; 415:96–99
90. Christians ES, Yan L-J, Benjamin IJ: Heat shock factor 1 and heat shock proteins: Critical partners in protection against acute cell injury. *Crit Care Med* 2002; 30:S43–S50
91. Chen H-W, Hsu C, Lu T-S, et al: Heat shock pretreatment prevents cardiac mitochondrial dysfunction during sepsis. *Shock* 2003; 20:274–279
92. Hotchkiss R, Nunnally I, Lindquist S, et al: Hyperthermia protects mice against the lethal effects of endotoxin. *Am J Physiol Regul Integr Comp Physiol* 1993; 265: R1447–R1457
93. Larche J, Lancel S, Hassoun SM, et al: Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. *J Am Coll Cardiol* 2006; 48:377–385
94. Hotchkiss RS, Song SK, Neil JJ, et al: Sepsis does not impair tricarboxylic acid cycle in the heart. *Am J Physiol Cell Physiol* 1991; 260:50–57
95. Fernandes CJ, Iervolino M, Neves RA, et al: Intersitial myocarditis in sepsis. *Am J Cardiol* 1994; 74:958
96. Hotchkiss RS, Swanson PE, Freeman BD, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med* 1999; 27:1230–1248
97. Langenfeld JE, Machiedo GW, Lyons M, et al: Correlation between red blood cell deformability and changes in hemodynamic function. *Surgery* 1994; 116:859–867
98. Nevière R, Fauvel H, Chopin C, et al: Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis. *Am J Respir Crit Care Med* 2001; 163:218–225
99. Fauvel H, Marchetti P, Chopin C, et al: Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. *Am J Physiol Heart Circ Physiol* 2001; 280:1608–1614
100. Carlsson DL, Willis MS, White DJ, et al: Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. *Crit Care Med* 2005; 33:1021–1028
101. Lancel S, Joulin O, Favory R, et al: Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction. *Circulation* 2005; 111:2596–2604
102. Hotchkiss RS, Swanson PE, Perren CJ, et al: Apoptosis in lymphoid and parenchymal cells during sepsis: Findings in normal and T- and B-cell-deficient mice. *Crit Care Med* 1997; 25:1298–1307
103. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. *J Exp Med* 1989; 169:823–832
104. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. *N Engl J Med* 1989; 321:280–287
105. Kumar A, Zanotti S, Bunnell G, et al: Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. *Crit Care Med* 2005; 33:331–340
106. Kumar A, Bunnell E, Lynn M, et al: Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid analogue E5531. *Chest* 2004; 126:860–867
107. Baumgarten G, Knuefermann P, Schuhmacher G, et al: Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. *Shock* 2006; 25:43–49
108. Knuefermann P, Nemoto S, Misra A, et al: CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. *Circulation* 2002; 106:2608–2615
109. Tavener SA, Kubes P: Cellular and molecular mechanisms underlying LPS-associated myocyte impairment. *Am J Physiol Heart Circ Physiol* 2006; 290:H800–H806
110. Knuefermann P, Sakata Y, Baker JS, et al: Toll-like receptor 2 mediates Staphylococ-

- cus aureus-induced myocardial dysfunction and cytokine production in the heart. *Circulation* 2004; 110:3693–3698
111. Kumar A, Thota V, Dee L, et al: Tumor necrosis factor α and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. *J Exp Med* 1996; 183:949–958
 112. Pathan N, Hemingway CA, Alizadeh AA, et al: Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. *Lancet* 2004; 363:203–209
 113. Kinugawa K, Takahashi T, Kohmoto O, et al: Nitric oxide-mediated effects of interleukin-6 on $[Ca^{2+}]_i$ and cell contraction in cultured chick ventricular myocytes. *Circ Res* 1994; 75:285–295
 114. Sugishita K, Kinugawa K, Shimizu T, et al: Cellular basis for the acute inhibitory effects of IL-6 and TNF- α on excitation-contraction coupling. *J Mol Cell Cardiol* 1999; 31:1457–1467
 115. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. *Nat Med* 2000; 6:164–170
 116. Garner LB, Willis MS, Carlson DL, et al: Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. *Am J Physiol Heart Circ Physiol* 2003; 285:2500–2509
 117. Chagnon F, Metz CN, Bucala R, et al: Endotoxin-induced myocardial dysfunction: Effects of macrophage migration inhibitory factor neutralization. *Circ Res* 2005; 96: 1095–1102
 118. Rubbo H, Darley-Usmar V, Freeman BA: Nitric oxide regulation of tissue free radical injury. *Chem Res Toxicol* 1996; 9:809–820
 119. Massion PB, Feron O, Dessy C, et al: Nitric oxide and cardiac function. *Circ Res* 2003; 93:388–398
 120. Haque R, Kan H, Finkel MS: Effects of cytokines and nitric oxide on myocardial E-C coupling. *Basic Res Cardiol* 1998; 93:86–94
 121. Arstall MA, Sawyer DB, Fukazawa R, et al: Cytokine-mediated apoptosis in cardiac myocytes: The role of inducible nitric oxide synthase induction and peroxynitrite generation. *Circ Res* 1999; 85:829–840
 122. Brune B: The intimate relation between nitric oxide and superoxide in apoptosis and cell survival. *Antioxid Redox Signal* 2005; 7:497–507
 123. Ferdinandy P, Daniel H, Ambrus I, et al: Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. *Circ Res* 2000; 87:241–247
 124. Balligand J-L, Ungureanu D, Kelly RA, et al: Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. *J Clin Invest* 1993; 91:2314–2319
 125. Ullrich R, Scherrer-Crosbie M, Bloch KD, et al: Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. *Circulation* 2000; 102:1440–1446
 126. Kumar A, Brar R, Wang P, et al: Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. *Am J Physiol Regul Integr Comp Physiol* 1999; 276:R265–R276
 127. Ichinose F, Hataishi R, Wu JC, et al: A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice. *Am J Physiol Heart Circ Physiol* 2003; 285:H2524–H2530
 128. Ichinose F, Buys ES, Neilan TG, et al: Cardiomyocyte-specific overexpression of nitric oxide synthase 2 prevents myocardial dysfunction in murine models of septic shock. *Circ Res* 2007; 100:130–139
 129. Barouch LA, Harrison RW, Skaf MW, et al: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. *Nature* 2002; 416:337–339
 130. Schulz R, Dodge KL, Lopaschuk GD, et al: Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. *Am J Physiol Heart Circ Physiol* 1997; 272: 1212–1219
 131. Khadour FH, Panas D, Ferdinandy P, et al: Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. *Am J Physiol Heart Circ Physiol* 2002; 283:H1108–H1115
 132. Wang W, Sawicki G, Schulz R: Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. *Cardiovasc Res* 2002; 53:165–174
 133. Chen Y, Traverse JH, Du R, et al: Nitric oxide modulates myocardial oxygen consumption in the failing heart. *Circulation* 2002; 106:273–279
 134. Klabunde RE, Ritger RC: NG-monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. *Biochem Biophys Res Commun* 1991; 178:1135–1140
 135. Cobb JP, Natanson C, Hoffman WD, et al: N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. *J Exp Med* 1992; 176:1175–1182
 136. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. *Lancet* 1991; 338:1557–1558
 137. Petros A, Lamb G, Leone A, et al: Effects of a nitric oxide synthase inhibitor in humans with septic shock. *Cardiovasc Res* 1994; 28: 34–39
 138. Brodie BR, Grossman W, Mann T, et al: Effects of sodium nitroprusside on left ventricular diastolic pressure-volume relations. *J Clin Invest* 1977; 59:59–68
 139. Paulus WJ, Vantrimpont PJ, Shah AM: Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. *Circulation* 1994; 89:2070–2078
 140. Wink DA, Hanbauer I, Krishna MC, et al: Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. *Proc Natl Acad Sci U S A* 1993; 90:9813–9817
 141. Nisoli E, Clementi E, Paolucci C, et al: Mitochondrial biogenesis: The role of endogenous nitric oxide. *Science* 2003; 299:896–899
 142. Nisoli E, Falcone S, Tonello C, et al: Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. *Proc Natl Acad Sci U S A* 2004; 101:16507–16512
 143. Opie LH: Receptors and signal transduction. In: *Heart Physiology: From Cell to Circulation*. Fourth Edition. Opie LH (Ed). London, Lippincott Williams & Wilkins, 2004, pp 186–220
 144. Bocking JK, Sibbald WJ, Holliday RL, et al: Plasma catecholamine levels and pulmonary dysfunction in sepsis. *Surg Gynecol Obstet* 1979; 148:715–719
 145. Bernardin G, Strosberg AD, Bernard A, et al: β -adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. *Intensive Care Med* 1998; 24:1315–1322
 146. Hahn PY, Wang P, Tait SM, et al: Sustained elevation in circulating catecholamine levels during polymicrobial sepsis. *Shock* 1995; 4:269–273
 147. Macarthur H, Westfall TC, Riley DP, et al: Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. *Proc Natl Acad Sci U S A* 2000; 97:9753–9758
 148. Tang C, Liu M-S: Internal externalization followed by internalization of β -adrenergic receptors in rat heart during sepsis. *Am J Physiol Regul Integr Comp Physiol* 1996; 270:254–263
 149. Shepherd RE, Lang CH, McDonough KH: Myocardial adrenergic responsiveness after lethal and nonlethal doses of endotoxin. *Am J Physiol Heart Circ Physiol* 1987; 252: 410–416
 150. Gulick TS, Chung MK, Pieper SJ, et al: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. *Proc Natl Acad Sci U S A* 1989; 86:6753–6757
 151. Chung MK, Gulick TS, Rotondo RE, et al: Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. *Circ Res* 1990; 67: 753–763
 152. Matsuda N, Hattori Y, Akaishi Y, et al: Impairment of cardiac β -adrenoceptor cellular signaling by decreased expression of G α in septic rabbits. *Anesthesiology* 2000; 93: 1465–1473
 153. Böhm M, Kirchmayr R, Gierschik P, et al: Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. *Am J Med* 1995; 98:183–186

154. Wu L-L, Yang S-L, Yang R-C, et al: G protein and adenylate cyclase complex-mediated signal transduction in the rat heart during sepsis. *Shock* 2003; 19:533–537
155. Hare JM, Loh E, Creager MA, et al: Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. *Circulation* 1995; 92:2198–2203
156. Barth E, Radermacher P, Thiernemann C, et al: Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. *Crit Care Med* 2006; 34:307–313
157. Abi-Gerges N, Tavernier B, Mebazaa A, et al: Sequential changes in autonomic regulation of cardiac myocytes after *in vivo* endotoxin injection in rat. *Am J Respir Crit Care Med* 1999; 160:1196–1204
158. Zhong J, Hwang T-C, Adams HR, et al: Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. *Am J Physiol Heart Circ Physiol* 1997; 273:2312–2324
159. Liu S, Schreier KD: G protein-mediated suppression of L-type Ca²⁺ current by interleukin-1 beta in cultured rat ventricular myocytes. *Am J Physiol Cell Physiol* 1995; 268:339–349
160. Buckley JF, Singer M, Clapp LH: Role of KATP channels in sepsis. *Cardiovasc Res* 2006; 72:220–230
161. Wu L-L, Liu M-S: Altered ryanodine receptor of canine cardiac sarcoplasmic reticulum and its underlying mechanism in endotoxin shock. *J Surg Res* 1992; 53:82–90
162. Dong LW, Wu LL, Ji Y, et al: Impairment of the ryanodine-sensitive calcium release channels in the cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis. *Shock* 2001; 16:33–39
163. Cohen RI, Wilson D, Liu SF: Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3',5' (cyclic) phosphate-dependent and independent pathways. *Crit Care Med* 2006; 34:173–181
164. Yokoyama T, Vaca L, Rossen RD, et al: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. *J Clin Invest* 1993; 92:2303–2312
165. Grandel U, Fink L, Blum A, et al: Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. *Circulation* 2000; 102:2758–2764
166. Favory R, Lancel S, Marchetti P, et al: Endotoxin-induced myocardial dysfunction: evidence for a role of sphingosine production. *Crit Care Med* 2004; 32:495–501
167. Oral H, Dorn GW, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. *J Biol Chem* 1997; 272:4836–4842
168. Wu L-L, Ji Y, Dong L-W, et al: Calcium uptake by sarcoplasmic reticulum is impaired during the hypodynamic phase of sepsis in the rat heart. *Shock* 2001; 15:49–55
169. Wu L-L, Tang C, Dong L-W, et al: Altered phospholamban-calcium ATPase interaction in cardiac sarcoplasmic reticulum during the progression of sepsis. *Shock* 2002; 17:389–393
170. Fauvel H, Marchetti P, Obert G, et al: Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. *Am J Respir Crit Care Med* 2002; 165:449–455
171. Joshi MS, Julian MW, Huff JE, et al: Calcineurin regulates myocardial function during acute endotoxemia. *Am J Respir Crit Care Med* 2006; 173:999–1007
172. Wang W, Schulze CJ, Suarez-Pinzon WL, et al: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. *Circulation* 2002; 106:1543–1549
173. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. *Cardiovasc Res* 2003; 57:426–433
174. Wu L-L, Tang C, Liu M-S: Altered phosphorylation and calcium sensitivity of cardiac myofibrillar proteins during sepsis. *Am J Physiol Regul Integr Comp Physiol* 2001; 281:R408–R416
175. Takeuchi K, del Nido PJ, Ibrahim AE, et al: Increased myocardial calcium cycling and reduced myofilament calcium sensitivity in early endotoxemia. *Surgery* 1999; 126:231–238
176. Heusch G, Schulz R, Rahimtoola SH: Myocardial hibernation: A delicate balance. *Am J Physiol Heart Circ Physiol* 2005; 288:984–999